业界动态监管公开信息 · FDA

Genuine Virgin Aloe Corp(以 Triderma 名义经营)- 679744 - 11/03/2026

FDA Drugs · 2026-11-13 23:38

正文 · 中文译文

结案函 Genuine Virgin Aloe Corp(以 Triderma 名义经营) MARCS-CMS 679744 — 2026年11月3日 更多警告函 警告函 关于警告函与结案函 参考编号: FEI 3008235829 产品: 药品 收件人: 收件人姓名 Gloria J. Vanderlaan 女士 收件人职务 创始人兼首席执行官 Genuine Virgin Aloe Corp(以 Triderma 名义经营) 1395 N. Manassero St. 阿纳海姆,加利福尼亚州 92807 美国 gloria@triderma.com 签发办公室: 药品质量运营四部 美国 secondary 签发办公室 美国 尊敬的 Vanderlaan 女士: 美国食品药品监督管理局(FDA)已完成对贵公司针对我方2024年7月1日警告函 CMS 679744 所作纠正措施的评估。 根据我们的评估,贵公司似乎已解决本警告函中所含的违规问题。未来的 FDA 检查和监管活动将进一步评估这些纠正措施的充分性和可持续性。 本函并不免除您或贵公司采取一切必要步骤以确保持续遵守《联邦食品、药品和化妆品法案》及其实施细则或其他相关法律授权的责任。 FDA 期望您和贵公司保持合规,并将继续监测您的合规状态。若在后续检查中或通过其他方式发现违规行为,本函不会排除任何未来的监管行动。 此致, /S Andrew Haack 合规官 药品质量三部 生产质量办公室 合规办公室 药品评价与研究中心 内容截至: 2026年11月13日 受监管产品 药品

正文 · 英文原文

CLOSEOUT LETTER Genuine Virgin Aloe Corp dba Triderma MARCS-CMS 679744 — November 03, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Reference #: FEI 3008235829 Product: Drugs Recipient: Recipient Name Ms. Gloria J. Vanderlaan Recipient Title Founder and CEO Genuine Virgin Aloe Corp dba Triderma 1395 N. Manassero St. Anaheim, CA 92807 United States gloria@triderma.com Issuing Office: Division of Pharmaceutical Quality Operations IV United States Secondary Issuing Offices United States Dear Ms. Vanderlaan: The Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our Warning Letter CMS 679744 dated July 1, 2024. Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections. This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The FDA expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means. Sincerely, /S Andrew Haack Compliance Officer Division of Drug Quality III Office of Manufacturing Quality Office of Compliance Center for Drug Evaluation and Research Content current as of: 11/13/2026 Regulated Product(s) Drugs

English
Genuine Virgin Aloe Corp dba Triderma - 679744 - 11/03/2026
内容仅供参考,不构成诊疗建议,不能替代执业医师的诊断。

← 返回元界